Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the impact of supportive measures on the drug adherence of patients with essential hypertension
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Set of supportive tools/measures vs. standard care | Behavioral |
| Measure | Description | Time Frame |
|---|---|---|
| Drug adherence in patients (daily proportion of patients taking one tablet of the prescribed hypertensive therapy as prescribed) |
| Measure | Description | Time Frame |
|---|---|---|
| Compliance and persistence between randomized groups over time. | ||
| To assess discrepancies between pill counts, Morisky questionnaire and electronic monitoring to estimate patient adherence to prescribed therapy |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Basel | +41 61 324 1111 | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Investigative Centers | Germany | |||||
| Novartis |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 19300114 | Derived | Dusing R, Handrock R, Klebs S, Tousset E, Vrijens B. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE. J Hypertens. 2009 Apr;27(4):894-901. doi: 10.1097/HJH.0b013e328323f9be. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D010349 | Patient Compliance |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010342 | Patient Acceptance of Health Care |
| D000074822 | Treatment Adherence and Compliance |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| To assess the relation between drug exposure and BP reduction. |
| To assess the relation between drug exposure and the likelihood to switch to valsartan 160 mg plus HCTZ 12.5 mg |
| To assess the safety and tolerability of valsartan 160 mg and valsartan 160 mg plus |
| HCTZ 12.5 mg. |
| Basel |
| Switzerland |
| D015438 | Health Behavior |
| D001519 | Behavior |